ArticlesCatheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial
Introduction
Patients with ventricular tachycardia (VT) and a history of myocardial infarction are at high risk of recurrent VT, ventricular fibrillation (VF), and sudden death. In patients with high risk of ventricular arrhythmia, intervention with an implantable cardioverter defibrillator (ICD) reduces rates of sudden cardiac death and total mortality compared with treatment with antiarrhythmic drugs.1, 2, 3, 4, 5 However, patients who receive ICD shocks have a decreased quality of life (especially if five or more shocks per year are delivered6) and increased mortality compared with patients who do not receive shocks, even if the shocks are inappropriate.7 Furthermore, ICDs do not prevent sudden cardiac death in 3–7% of patients.8 Drug treatment—especially amiodarone in combination with β blockers—can reduce the number of ICD interventions, but lifetime intake is necessary and it is associated with serious adverse events.9
Catheter ablation of VT can effectively reduce the number of ICD interventions, especially since the introduction of three-dimensional mapping systems that allow not only activation mapping during tachycardia but also substrate mapping during sinus rhythm.10, 11 The benefits of catheter ablation have been shown by studies in large multicentre trials.12, 13 Most recently, a three-centre study in patients with unstable VT, cardiac arrest, or syncope with inducible VT showed that the incidence of ICD interventions was lower in patients assigned to prophylactic catheter ablation plus defibrillator implantation than in patients assigned to defibrillator implantation alone.14 The Ventricular Tachycardia Ablation in Coronary Heart Disease (VTACH) study was designed to assess prophylactic VT ablation followed by implantation of a cardioverter defibrillator in patients with previous myocardial infarction, first episode of stable VT, and reduced left-ventricular function.
Section snippets
Patients
The VTACH study was a prospective, open, multicentre, randomised controlled trial. Institutional review board approval was obtained at each of the participating centres. Enrolment began in August, 2002, lasting 42 months, and follow-up was completed in January, 2006.
Patients aged 18–80 years were eligible for enrolment if they had an indication for an ICD as secondary prevention after documented stable clinical VT without any reversible cause, coronary artery disease, previous myocardial
Results
Figure 1 shows the trial profile. 110 patients were enrolled in 16 participating European centres in Germany (13 centres), Switzerland (one), Czech Republic (one), and Denmark (one). The intention-to-treat population consisted of 107 patients because two patients withdrew consent immediately after randomisation without any follow-up data and one patient with non-ischaemic VT had to be excluded from the study (violation of protocol inclusion criterion). Table 1 shows the demographic and baseline
Discussion
The VTACH trial investigated the role of prophylactic catheter ablation followed by defibrillator implantation in patients with a first episode of stable VT after myocardial infarction. In this trial, all patients were assigned to receive an ICD, even though patients with stable VT had not been included in three previous randomised trials of this device.1, 2, 3 The Antiarrhythmics Versus Implantable Defibrillators (AVID) registry showed that patients with stable VT might have a similar outcome
References (30)
- et al.
Quality of life in the Canadian Implantable Defibrillator Study (CIDS)
Am Heart J
(2002) - et al.
Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study
J Am Coll Cardiol
(2000) - et al.
Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to clinical presentation
J Am Coll Cardiol
(1999) - et al.
Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmias on the basis of data from 157 cases
Am Heart J
(1989) - et al.
Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: results and long-term follow up
J Am Coll Cardiol
(1994) - et al.
Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation
J Am Coll Cardiol
(2002) A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
N Engl J Med
(1997)- et al.
Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH)
Circulation
(2000) - et al.
Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable defibrillator against amiodarone
Circulation
(2000) - et al.
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicentre Automatic Defibrillator Implantation Trial Investigators
N Engl J Med
(1996)
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
N Engl J Med
Prognostic importance of defibrillator shocks in patients with heart failure
N Engl J Med
Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government
J Interv Card Electrophysiol
Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial
JAMA
Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping
Circulation
Cited by (0)
- ‡
Members listed at end of paper